Review Of Clinical Data From Gemin X Biotechnologies Inc.'s GX15-070 Program Presented At The 24th Annual Chemotherapy Foundation Symposium

MONTREAL--(BUSINESS WIRE)--Gemin X Biotechnologies Inc. announced today that a review of Phase 1 clinical data obtained with the company’s lead product candidate, GX15-070, was presented yesterday by Dr. Susan O’Brien, principal investigator and leukemia specialist with The University of Texas M.D. Anderson Cancer Center, during the 24th Annual Chemotherapy Foundation Symposium. Currently in Phase 2 clinical trials, GX15-070 is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, thus restoring the natural cell death process of apoptosis.